SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Generics secures USFDA approval for Rizatriptan Benzoate Tablets

20 Sep 2012 Evaluate

Glenmark Generics Inc., USA a subsidiary of Glenmark Generics has been granted tentative approval for Rizatriptan Benzoate tablets from the United States Food and Drug Administration (USFDA), its generic version of Merck’s Maxalt tablets.

 According to IMS Health for the 12 month period ending June 2012, Rizatriptan Benzoate immediate release tablets achieved sales of $ 315 million.

Glenmark’s current portfolio consists of 81 products authorized for distribution in the U.S mark place and 41 ANDA’s pending approval with the U.S. FDA.

Glenmark Generics is a subsidiary of Glenmark Pharmaceuticals (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America, a developing EU presence and Argentina and maintains marketing front-ends in these countries.

Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×